Gossamer Bio’s (GOSS) “Buy” Rating Reaffirmed at HC Wainwright

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $10.00 price objective on the stock.

Other analysts have also issued reports about the company. Piper Sandler reiterated an “overweight” rating and set a $15.00 price objective on shares of Gossamer Bio in a research note on Wednesday, March 27th. The Goldman Sachs Group cut their price target on shares of Gossamer Bio from $9.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 6th. Finally, Wedbush started coverage on Gossamer Bio in a report on Friday, April 5th. They issued an “outperform” rating and a $4.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.65.

Gossamer Bio Stock Performance

Shares of NASDAQ GOSS traded up $0.03 during mid-day trading on Monday, reaching $0.77. 7,378,047 shares of the company’s stock were exchanged, compared to its average volume of 1,309,957. The firm has a 50-day moving average price of $1.11 and a two-hundred day moving average price of $0.93. The company has a debt-to-equity ratio of 3.14, a current ratio of 5.94 and a quick ratio of 5.94. The firm has a market capitalization of $173.33 million, a price-to-earnings ratio of -0.54 and a beta of 1.84. Gossamer Bio has a 52 week low of $0.45 and a 52 week high of $1.88.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Tuesday, March 5th. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). Analysts predict that Gossamer Bio will post -0.75 EPS for the current year.

Insiders Place Their Bets

In other Gossamer Bio news, CEO Faheem Hasnain sold 23,172 shares of the stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $1.16, for a total value of $26,879.52. Following the completion of the sale, the chief executive officer now owns 120,293 shares in the company, valued at approximately $139,539.88. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold a total of 33,620 shares of company stock valued at $39,682 in the last quarter. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Gossamer Bio

Institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its position in shares of Gossamer Bio by 178.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 91,246 shares of the company’s stock worth $76,000 after purchasing an additional 58,428 shares in the last quarter. Financial Advocates Investment Management purchased a new stake in Gossamer Bio during the 3rd quarter valued at about $61,000. Platinum Investment Management Ltd. raised its holdings in Gossamer Bio by 126.7% in the third quarter. Platinum Investment Management Ltd. now owns 5,357,778 shares of the company’s stock worth $4,462,000 after buying an additional 2,994,608 shares during the last quarter. Silverarc Capital Management LLC purchased a new position in Gossamer Bio in the third quarter worth about $5,105,000. Finally, Federated Hermes Inc. lifted its position in Gossamer Bio by 326.2% in the 3rd quarter. Federated Hermes Inc. now owns 3,994,723 shares of the company’s stock valued at $3,328,000 after acquiring an additional 3,057,419 shares in the last quarter. 81.23% of the stock is owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.